FDA gives the green signal for Abbott’s finger prick-free blood sugar proportion monitoring device

Date: 2017-09-29   Author: Saipriya Iyer  Category: #news

FDA gives the green signal for Abbott’s finger prick-free blood sugar proportion monitoring device

The U.S. Food and Drug Administration (FDA) has officially approved the FreeStyle Libre, a bottle cap-sized wearable sensor device developed by Abbot laboratories, a U.S. based healthcare firm, to continuously check the glucose levels in diabetic patients. As per reliable sources, the equipment is water-resistant and can be efficiently worn while swimming as well. It is also equipped with advanced technology that eliminates the need for daily finger pricking and can be easily scanned over fabrics & clothes.  In addition, the equipment comprises a small reader that scans the sensor, gathers real-time data about the glucose levels in the patient, and examines the sugar level measurements taken during the last eight hours. Abbot’s move has been touted to prove highly beneficial for the healthcare fraternity.

Earlier in 2016, FDA had approved a similar type of product introduced by the Dexcom Incorporation, a medical device manufacturing firm based in the U.S. Unlike Abbot’s freestyle Libre, however, the tool was supposed to be calibrated with a finger prick two times in a day to measure the glucose levels in the diabetics, which is where Abbot’s equipment takes an upper hand. After receiving the approval for its wearable sensor equipment, Abbott’s shares depicted a rise of 3.6%, closing at USD 54 per share, while Dexcom’s shares plunged to 34%, cite sources.

If reports are to be believed, the cost of the wearable sensor Libre in the U.S. will be equivalent to its costs across Europe. At present, the sensor & reader cost around USD 140 for a single patient in Europe and necessitates replacement every ten days. The yearly cost amounts to USD 1900 across the region, which also encompasses the price of one reader and twenty-six sensors.

The U.S. houses close to 30 million diabetic patients, many among which are reported to be using standard glucose monitoring devices that require multiple finger pricking. In addition, these devices display only the current glucose level in the patients. Abbott’s freestyle Libre device, on the other hand, helps in continuously monitoring the glucose levels in the patients, which would undoubtedly prove to be highly beneficial for diabetic patients. Experts cite that the device is likely to substantially impact the product landscape of the United States medical device market in the forthcoming years.



About Author


Saipriya Iyer linkdin-boxtwitter

Saipriya Iyer

Saipriya Iyer currently works as a content developer for AlgosOnline. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her belt, she has dabbled with website...

Read More

Post Recommendents

Global Automotive Lighting Actuator Market: Rising Impressive Business Opportunities Analysis Forecast By 2027

Author: Ashwin Naphade

This report provides a strategic analysis of the Global Automotive Lighting Actuator market and the growth estimates for the forecast period. This report also provides market sizing and forecasts for the Global Automotive Lighting Actuator market....


Global Crankshaft Timing Gear Market: Industry Development Scenario and Forecast to 2027

Author: Ashwin Naphade

Market Study Report adds new report on Global Crankshaft Timing Gear Market Research, which contains company information, geographical data and market analysis about this industry for all stakeholders involved in or wanting to get into this market...


Global Camshaft Timing Gear Market Offered in New Research Forecast through 2027

Author: Ashwin Naphade

The Global Camshaft Timing Gear Market 2027 Market Research Report is a professional and in-depth study on the current state of the Camshaft Timing Gear . Development policies and plans are discussed as well as manufacturing processes and cost str...